NEOADJUVANT THERAPY WITH IMMUNE CHECKPOINT BLOCKADE AND CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH INTERMEDIATE OR HIGH-RISK RHABDOMYOSARCOMA (SIOP 2026) - Oct 23, 2026 - Abstract #OP146; Pres time: Sep 17, 2026; 02:15 PM - 02:30 PM; Location: Room 304; P1/2 | "However, the immune remodeling mechanisms of neoadjuvant chemoimmunotherapy and reliable predictive biomarkers in pediatric RMS remain poorly characterized. We performed an interim analysis of a multicenter, open-label, phase 1/2 trial (NCT06456892) evaluating neoadjuvant pucotenlimab (a humanized anti-PD-1 monoclonal antibody) plus risk-stratified chemotherapy in 39 patients aged 1–18 years with newly diagnosed intermediate-to-high-risk RMS... Our sequencing analyses systematically characterize the TIME remodeling induced by the combination regimen, identify multiple predictive biomarkers for treatment response, and establish a mechanistic basis for personalized immunotherapy in this high-risk patient population. Hide"
Checkpoint block • Checkpoint inhibition • Clinical • IO biomarker • Pediatrics • Rhabdomyosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CD68 • CD8 • PD-L1
|